To evaluate the effect of Zinc sulfate on growth indexes and hepatitis B antibody titer in premature neonates

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201010255008N1

Enrollment

146

Registered

2010-11-21

Start date

2010-10-07

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Zinc deficiency. Dietary zinc deficiency

Interventions

case group: 3 mg of zinc sulfate, daily for 6 months

Intervention 1: control group: nothing. Intervention 2: case group: 3 mg of zinc sulfate, daily for 6 months.

Treatment - Drugs

control group: nothing

Eligibility

Sex/Gender

All

Age

28 Years to 36 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria: 28-36 gestational age , lack of congenital or organic disease, breast feeding. The exclusion criteria : Formula feeding, congenital or organic disease, contracting any disease during study, taking Zinc sulfate irregularly .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Weight. Timepoint: birth time and monthly. Method of measurement: Pan scale.;Lenght. Timepoint: birth time and monthly. Method of measurement: lenght scale.;Head Circumference. Timepoint: birth time and monthly. Method of measurement: meter.;Antibody titer. Timepoint: 1 month after injection of hepatit B vaccin at six month after birth. Method of measurement: Elisa method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mitr Hemmati

Kermanshah University of Medical Sciences

mitra_hemmati@yahoo.com+98 831423763015

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026